Bleichmar Fonti & Auld LLP announces that investors in Embecta Corp. have until August 17, 2026, to seek lead plaintiff appointment in a securities fraud class action filed after the company's stock dropped 57.8% on May 5, 2026. The lawsuit, pending in the U.S. District Court for the District of New Jersey under the caption Apitz-Grossman v. Embecta Corp., et al., alleges that Embecta misled investors about the strength of its insulin pen needle product category while facing significant competition and overall market softness. On May 5, 2026, Embecta reported disappointing second-quarter results below guidance, citing share loss within its pen needle category and a decline in insulin pen prescriptions, and slashed its quarterly dividend from $0.15 to $0.01 per share. The stock fell from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026. The firm represents investors on a contingency fee basis with no upfront costs.
Embecta CorpSecurities fraud class action filed after stock dropped 57.8% on disappointing Q2 results and dividend cut.